English
Structure via PubChem · Public domain (PubChem)
ranirestat
Sign in to saveRanirestat (also known as AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy by Dainippon Sumitomo Pharma and PharmaKyorin. It has been granted orphan drug status. The drug is to be used orally.
Chemical data
- Formula
- C17H11BrFN3O4
- Molecular weight
- 420.2 g/mol
- IUPAC name
- (3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone
- SMILES
- C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
- InChIKey
- QCVNMNYRNIMDKV-QGZVFWFLSA-N
- XLogP
- 1.3
- Polar surface area
- 88.5 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- polyneuropathy, diabetic neuropathy
via ChEMBL · EBI
Research
48 papers- Ranirestat Improves Electrophysiologic but not Clinical Measures of Diabetic Polyneuropathy: A Meta-Analysis.Indian journal of endocrinology and metabolism · 2022
- Evaluation of ranirestat for the treatment of diabetic neuropathy.Expert opinion on drug metabolism & toxicology · 2014
- Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.Journal of clinical pharmacology · 2020
- Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.Expert opinion on investigational drugs · 2008
- Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy.Journal of diabetes research · 2019
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 418.992
Show 5 more facts
- canonical SMILES
- C1C(=O)NC(=O)C12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
- chemical formula
- C₁₇H₁₁BrFN₃O₄
- isomeric SMILES
- C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
- subject has role
- enzyme inhibitor
- Commons category
- Ranirestat
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
5 sectionsContents
- Trials
- Mechanism of action
- Efficacy
- See also
- References
Ranirestat (also known as AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy by Dainippon Sumitomo Pharma and PharmaKyorin. It has been granted orphan drug status. The drug is to be used orally.
==Trials== A Canadian Phase III clinical trial has been completed. Phase III trials in Europe and the US started in June 2009 and are expected to complete in April 2013.
Excerpted from Wikipedia’s “ranirestat” article, available under the CC BY-SA 4.0 licence.